NCT02113982 2024-08-01Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid LeukemiaStemline Therapeutics, Inc.Phase 1/2 Completed138 enrolled 23 charts 2 FDA